Trial Parameters
Condition Hepatocellular Carcinoma
Sponsor AstraZeneca
Study Type OBSERVATIONAL
Phase N/A
Enrollment 246
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2025-04-14
Completion 2029-02-28
Brief Summary
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea.
Eligibility Criteria
Inclusion criteria: 1. Patients eligible for the study drugs according to the approved label in Korea 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion criteria: 1. Other off-label indications according to the approved label in South Korea 2. Current participation in any interventional trial
Related Trials
NCT06406634
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the
View Trial →
NCT05992584
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
View Trial →
NCT06950827
Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
View Trial →